Literature DB >> 7092355

Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes.

C Callery, A J Cochran, D J Roe, W Rees, S D Nathanson, J K Benedetti, R M Elashoff, D L Morton.   

Abstract

To establish clinical and histologic determinants of survival, records of all UCLA patients with resectable melanoma metastatic to the lymph nodes during the years 1954-1976 were reviewed. These 150 patients were treated first with wide excision, lymphadenectomy, and with radiation/chemotherapy and/or additional surgery only if further recurrences developed. None received adjuvant immunotherapy or chemotherapy. In 97 of 139 patients with identified primary tumors, slides of the primary lesion were reviewed. Putative prognostic factors included age, sex, parity, site of primary tumor, presence of satellitosis, clinical status of nodes, histologic characteristics of primary lesion (Clark's level, thickness of tumor, presence/width of ulceration, and number of mitoses/HPF), time from biopsy of primary tumor to lymphadenectomy, and number of positive nodes. kaplan-Meier estimates of survival for the entire group at one, two, five, and ten years were 73, 55, 37, and 33%, respectively. Median follow-up period of survivors was four years. Univariate analyses using the log-rank test showed that thickness of the primary lesion (p less than 0.001), width of ulceration (p = 0.003), absence of ulceration (p = 0.024), and number of positive nodes (p = 0,.033) were prognostic for survival. In multivariate analysis by the Cox procedure, thickness of the primary (p = 0.001) and number of melanoma-containing nodes (p = 0.043) were prognostic for survival. Location of the primary tumor became marginally significant (p = 0.12) in the multrivariate model. These findings demonstrate the prognostic importance of characteristics of both the primary lesion and extent of regional dissemination. Future prospective randomized trials for (adjuvant) therapy of Stage II melanoma should be stratified by these variables.

Entities:  

Mesh:

Year:  1982        PMID: 7092355      PMCID: PMC1352500          DOI: 10.1097/00000658-198207000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  20 in total

1.  Biostatistical basis of elective node dissection for malignant melanoma.

Authors:  J G Fortner; J Woodruff; D Schottenfeld; B Maclean
Journal:  Ann Surg       Date:  1977-07       Impact factor: 12.969

2.  Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study.

Authors:  T K Gupta
Journal:  Ann Surg       Date:  1977-08       Impact factor: 12.969

3.  Assessment of prognosis in patients with malignant melanoma.

Authors:  R M Mackie; D C Carfrae; A J Cochran
Journal:  Lancet       Date:  1972-09-02       Impact factor: 79.321

4.  Method of assessing prognosis in patients with malignant melanoma.

Authors:  A J Cochran
Journal:  Lancet       Date:  1968-11-16       Impact factor: 79.321

5.  The classification of malignant melanoma and its histologic reporting.

Authors:  V J McGovern; M C Mihm; C Bailly; J C Booth; W H Clark; A J Cochran; E G Hardy; J D Hicks; A Levene; M G Lewis; J H Little; G W Milton
Journal:  Cancer       Date:  1973-12       Impact factor: 6.860

6.  Prognostic significance of lymph node dissection in the treatment of malignant melanoma.

Authors:  H S Goldsmith; J P Shah; D H Kim
Journal:  Cancer       Date:  1970-09       Impact factor: 6.860

7.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

8.  Malignant melanoma. A REVIEW OF ') YEARS' experience in Glasgow, Scotland.

Authors:  A J Cochran
Journal:  Cancer       Date:  1969-05       Impact factor: 6.860

9.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

Authors:  W H Clark; L From; E A Bernardino; M C Mihm
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

10.  Prognostic factors in patients undergoing lymphadenectomy for malignant melanoma.

Authors:  M H Cohen; A S Ketcham; E L Felix; S H Li; M M Tomaszewski; J Costa; A S Rabson; R M Simon; S A Rosenberg
Journal:  Ann Surg       Date:  1977-11       Impact factor: 12.969

View more
  14 in total

1.  A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate.

Authors:  W A Cassel; D R Murray
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients.

Authors:  Markwin G Statius Muller; Paul A M van Leeuwen; Paul J van Diest; Rik Pijpers; Robert J Nijveldt; Ronald J C L M Vuylsteke; Sybren Meijer
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

3.  The prognosis of melanoma patients with metastases to two or more lymph node areas.

Authors:  R J Barth; D J Venzon; A R Baker
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

4.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

5.  Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.

Authors:  R C Jones; M Kelley; R K Gupta; J A Nizze; R Yee; Z Leopoldo; K Qi; S Stern; D L Morton
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

Review 6.  Management of the regional lymph nodes in patients with cutaneous malignant melanoma.

Authors:  A J Cochran; D R Wen; D L Morton
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

7.  Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group.

Authors:  D L Morton; J F Thompson; R Essner; R Elashoff; S L Stern; O E Nieweg; D F Roses; C P Karakousis; N Mozzillo; D Reintgen; H J Wang; E C Glass; A J Cochran
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

8.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

9.  Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic.

Authors:  D L Morton; L Wanek; J A Nizze; R M Elashoff; J H Wong
Journal:  Ann Surg       Date:  1991-10       Impact factor: 12.969

10.  Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis.

Authors:  D G Coit; A Rogatko; M F Brennan
Journal:  Ann Surg       Date:  1991-11       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.